Publications by authors named "Bohyun Jeon"
Article Synopsis
- Heterologous boost regimens involving an mRNA vaccine after a DNA vaccine are gaining interest for enhancing immunity against SARS-CoV-2.
- In a clinical trial with 32 participants, those who received an mRNA vaccine 6 to 8 months after the GLS-5310 DNA vaccine reported no adverse events, indicating a good safety profile.
- The study found significant improvements in immune responses, with increased antibody and T-cell levels, marking it as the first report on immune responses from this specific vaccination strategy.
pGO-1002, a non-viral DNA vaccine that expresses both spike and ORF3a antigens of SARS-CoV-2, is undergoing phase 1 and phase 2a clinical trials in Korea and the US. A preclinical repeated-dose toxicity study in New Zealand white rabbits in compliance with Good Laboratory Practice (GLP) was conducted to assess the potential toxicity, local tolerance, and immunogenicity of the vaccine and GeneDerm suction device. The dose rate was 1.
View Article and Find Full Text PDFArticle Synopsis
- The CoV2-001 phase I trial tested the GLS-5310 DNA vaccine for safety and immune response over 48 weeks with 45 participants who had not previously been vaccinated.* -
- Participants received two doses of the vaccine, administered intradermally at varying doses and intervals, and the vaccine was found to be well-tolerated with no serious side effects.* -
- The results showed high antibody and T cell responses, with 95.5% of participants producing anti-spike antibodies and 97.8% showing T cell responses, highlighting the vaccine's strong immunogenicity compared to other vaccines.*
MicroRNAs of miR-17-92 cluster increase gene expression by targeting mRNA-destabilization pathways.
Biochim Biophys Acta Gene Regul Mech
June 2018
MicroRNAs (miRNAs) of the miR-17-92 cluster are overexpressed in human cancers, and their enforced expression is tumorigenic in mouse models. A number of genes are reported to be targets of these miRNAs and are implicated in their tumorigenic potential. However, the mode of action by miRNAs suggests that global analysis of their targets is required to understand their cellular roles.
View Article and Find Full Text PDFGlobal analysis of AGO2-bound RNAs reveals that miRNAs induce cleavage of target RNAs with limited complementarity.
Biochim Biophys Acta Gene Regul Mech
November 2017
Among the four Argonaute family members in mammals, only AGO2 protein retains endonuclease activity and facilitates cleavage of target RNAs base-pairing with highly complementary guide RNAs. Despite the deeply conserved catalytic activity, only a small number of targets have been reported to extensively base pair with cognate miRNAs to be cleaved by AGO2. Here, we analyzed AGO2-bound RNAs by CrossLinking ImmunoPrecipitation (CLIP) of genetically modified cells that express epitope-tagged AGO2 from the native genomic locus.
View Article and Find Full Text PDF